Close Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Close Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$498K	Hold	19,000	–	–	0.01%	102
2026 Q1	$448K	Hold	19,000	–	–	0.01%	107
2025 Q4	$552K	Sell	19,000 -19,000	-50%	-$486K	0.01%	101
2025 Q3	$716K	Sell	38,000 -26,774	-41%	-$422K	0.02%	91
2025 Q2	$909K	Hold	64,774	–	–	0.03%	84
2025 Q1	$1.01M	Hold	64,774	–	–	0.03%	80
2024 Q4	$901K	Hold	64,774	–	–	0.03%	80
2024 Q3	$602K	Hold	64,774	–	–	0.02%	94
2024 Q2	$602K	Buy	+64,774	New	+$586K	0.02%	90

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Close Asset Management's ARQT Position: Q2 2026 in Review

Close Asset Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 19,000 shares worth $498K. The position accounts for 0.01% of the portfolio, ranked #102.

Close Asset Management first reported a position in ARQT in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.01M in Q1 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Close Asset Management held 19,000 shares of Arcutis Biotherapeutics worth $498K as of Q2 2026.
Close Asset Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up 0.01% of Close Asset Management's portfolio in Q2 2026, its #102 holding.
Close Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
Close Asset Management's Arcutis Biotherapeutics position peaked at $1.01M in Q1 2025.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.